secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001193125-26-005470
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics reports ~$514M cash; President/COO resigns, CEO assumes President role; new director appointed
--------------------------------------------------------------------------------

- Fariborz Kamal resigned as President/COO effective Dec 31, 2025; transitions to part-time Chief Technical Advisor.
- CEO David Kirn appointed President as of Jan 1, 2026, in addition to CEO role.
- Glenn Sblendorio appointed to Board as Class I director effective Jan 5, 2026, serving on Compensation and Science/Technology Committees.
- Preliminary cash, cash equivalents and marketable securities ~$514M as of Dec 31, 2025 (unaudited, subject to closing).
- Mr. Sblendorio received initial option for 45,000 shares at $7.30 exercise price; annual cash retainer of $40,000 plus committee fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526005470/0001193125-26-005470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312526005470/fdmt-20251231.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-005470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer